Innoviva, Inc. (NASDAQ: INVA), based in California, USA, is a forward-looking biopharmaceutical company committed to bringing transformative, innovative medical solutions to patients worldwide. The company is deeply embedded in the field of respiratory medication, primarily focusing on the successful commercialization of unique, patented therapies for chronic obstructive pulmonary disease (COPD) and asthma.
Initially founded in 1996 as Theravance, Innoviva was rebranded in 2016 to better reflect its strategic vision: breathing new life into pharmaceutical innovation. The company has a long track record of partnering with some of the leading global pharmaceutical and biotech companies, including GlaxoSmithKline (GSK), with whom Innoviva co-developed TRELEGY ELLIPTA, a once-daily, single inhaler triple therapy for COPD.
Innoviva's business model is unique. Rather than manufacturing and distributing therapies itself, Innoviva banks on its expertise in identifying, developing, and commercializing unique therapies sourced from global partners. The company then earns revenue through royalty payments received from these pharmaceutical partnerships.
Asides from TRELEGY ELLIPTA, its partnership with GSK has also given birth to other novel medicines that include RELVAR/BREO ELLIPTA, a once-daily combination of drugs to treat COPD and asthma, and ANORO ELLIPTA, another once-daily treatment for patients suffering from COPD.
Through the smart execution of its strategy, Innoviva continues to realize the value of its tremendous respiratory portfolio. The company has an impressive track record of transforming novel ideas into commercially successful therapies, reflecting its competitive edge in navigating the complex process of drug development through to commercialization.
Innoviva’s successful track record is further enhanced by its experienced management team comprised of accomplished leaders in the healthcare and pharmaceutical industries. Their combined wealth of knowledge and extensive industry relationships continuously drive the company's leadership in the development of novel treatments ensuring long-term value for its stakeholders.
Innoviva's business model and strategic alliances position it well to remain a significant contributor in the sphere of respiratory medication which contributes positively towards improving the quality of life for millions of patients globally.
Through decades of dynamic operations, Innoviva has successfully positioned itself as a global powerhouse in the commercialization of unique, cutting-edge respiratory solutions. Its commitment to continuous innovation and deep industry connections lay a solid foundation for potential growth and global impact in the years to come.